All In Biotech

Drug Trial Radar · NCT05653284

A Study of AK130 in Patients With Advanced Malignant Tumors

A Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of AK130 (TIGIT/TGF-β Bifunctional Fusion Protein) in Patients With Advanced Malignant Tumors

Last checked: Nov 19, 2026Latest source record: Aug 13, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

19

Actual

Start

Feb 9, 2023

Primary completion

Dec 12, 2023

Study completion May 30, 2024

Sponsor

Lead sponsor
AkesoIndustry
Sponsor type
Industry
First posted
Dec 16, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase I open label, dose-escalation and expansion study to evaluate the safety, tolerability, pharmacokinetics and anti-tumor activity of AK130 (TIGIT/TGF-β bifunctional fusion protein) in patients with advanced malignant tumors.

Conditions

  • Advanced Malignant Tumors

Interventions

  • AK130Drug

    IV infusion, specified dose on specified days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and severity of participants with adverse events (AEs)Time frame: From time ICF is signed until 90 days after last dose of AK130
  2. Number of participants with DLTsTime frame: During the first four weeks of treatment with AK130

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The Cancer Hospital Affiliated to Shandong First Medical University

    Jinan, Shandong, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.